Roche

In June 2006, Roche and Evotec have formed an alliance to jointly discover and develop compounds against a target for CNS diseases and other indications. Leveraging the expertise developed by Evotec on this target, and as part of their CNS drug discovery focus, Evotec and Roche will collaborate to identify inhibitors involved in the potential treatment of a range of diseases. Both companies believe that this target is of high priority and that partnering their respective drug discovery efforts and expertise will bring about the successful and timely discovery of new drugs.

18 May 2011
Phase II study with NR2B sub-type selective NMDA antagonist in treatment-resistant depression voluntarily terminated

1 Jul 2010
Evotec Starts Phase II Clinical Studies in Treatment-Resistant Depression

10 Mar 2010
Evotec Reports Good Progress in Product Development in Treatment-Resistant Depression in its Alliance with Roche

8 Sep 2009
Evotec starts Phase I with EVT 103, an NR2B-selective NMDA receptor antagonist

9 Mar 2009
Evotec and Roche to Develop EVT 101 for Treatment-Resistant Depression

21 Jun 2006
Evotec and Roche Form Global Alliance to Jointly Discover Novel Drugs

25 Apr 2006
Evotec Signs Two Significant Contracts with Roche

09 Jan 2006
Evotec Licenses Two Phase I Compounds with Disease Modifying Potential in Alzheimer's Disease

13 Apr 2005
Evotec OAI Extends Global Medicinal Chemistry Agreement with Roche

12 May 2004
Evotec OAI and Roche enter into Strategic Global Discovery Chemistry Agreement

25 Mar 2004
Evotec Neurosciences to licence NMDA receptor NR2B subunit selective antagonists from Roche

22 Oct 2003
Evotec OAI and Roche Sign Medicinal Chemistry Collaboration in Oncology

22 Aug 2002
Evotec OAI Grants Licence to Roche Diagnostics